Characteristics of rHBV responders and nonresponders
Characteristic . | Responder, n = 171 . | Nonresponder, n = 96 . | Odds ratio* . | P . |
|---|---|---|---|---|
| Median age, y (range) | 22.0 (0.2-58.6) | 33.8 (0.2-69) | 0.97 | < .001 |
| Age younger than 18 years, no. (%) | 72 (42.1) | 27 (28.1) | 1.86 | .02 |
| Sex, male, no. (%) | 102 (59.7) | 65 (67.7) | .71 | .19 |
| Diagnosis, no. (%) | ||||
| Acute leukemia | 76 (44.4) | 37 (38.5) | 1.28 | .35 |
| CML | 42 (24.6) | 27 (28.1) | 0.83 | .52 |
| Aplastic anemia | 11 (6.4) | 2 (2.1) | 3.23 | .13 |
| MDS | 14 (8.2) | 9 (9.4) | 0.86 | .74 |
| Lymphoma | 12 (7.0) | 13 (13.5) | 0.48 | .08 |
| Hemoglobinopathy | 6 (3.5) | 2 (2.1) | 1.70 | .52 |
| Immunodeficiency | 10 (5.9) | 6 (6.3) | 0.93 | .89 |
| Donor, no. (%) | ||||
| HLA-matched related | 111 (64.9) | 63 (65.6) | 0.96 | .91 |
| HLA-mismatched related | 14 (8.2) | 11 (11.5) | 0.69 | .38 |
| Unrelated | 46 (26.9) | 22 (22.9) | 1.23 | .47 |
| Graft type, no. (%) | ||||
| cBMT | 50 (29.2) | 27 (28.1) | 1.05 | .85 |
| cPBSCT | 5 (2.9) | 8 (8.4) | 0.33 | .06 |
| TCD-BM | 95 (55.6) | 49 (51.0) | 1.20 | .48 |
| TCD-PB | 20 (11.7) | 12 (12.5) | 0.93 | .85 |
| Cord blood | 1 (0.6) | — | — | — |
| Recipient pretransplantation anti-HBs, no. (%) | ||||
| Negative | 126 (73.7) | 71 (73.9) | 0.98 | .96 |
| Positive† | 37 (21.6) | 21 (21.9) | 0.98 | .96 |
| Unknown anti-HBs, negative core Ab (%) | 8 (4.7) | 4 (4.2) | 1.12 | .84 |
| Donor anti-HBs, no. (%) | ||||
| Negative | 84 (49.1) | 51 (53.1) | 0.85 | .53 |
| Positive‡ | 25 (14.6) | 15 (15.6) | 0.92 | .83 |
| Unknown§ | 62 (36.3) | 29 (31.3) | 1.25 | .41 |
| TBI regimen, no. (%) | 125 (73.5) | 72 (75.0) | .93 | .79 |
| DLI, no. (%) | 37 (21.6) | 28 (29.2) | .67 | .17 |
| Rituximab, no. (%) | 12 (7.0) | 11 (11.4) | .58 | .22 |
| Grade II-IV acute GVHD, no. (%) | 21 (12.3) | 22 (22.9) | .47 | .03 |
| Chronic GVHD, no. (%) | 15 (8.8) | 27 (28.1) | .24 | < .001 |
| Median d to first vaccine (range) | 703 (171-2765) | 778 (181-3444) | .99 | .012 |
| Median age at first vaccine, y (range) | 24 (1.6-60.6) | 36.1 (.8-69.6) | .97 | < .001 |
Characteristic . | Responder, n = 171 . | Nonresponder, n = 96 . | Odds ratio* . | P . |
|---|---|---|---|---|
| Median age, y (range) | 22.0 (0.2-58.6) | 33.8 (0.2-69) | 0.97 | < .001 |
| Age younger than 18 years, no. (%) | 72 (42.1) | 27 (28.1) | 1.86 | .02 |
| Sex, male, no. (%) | 102 (59.7) | 65 (67.7) | .71 | .19 |
| Diagnosis, no. (%) | ||||
| Acute leukemia | 76 (44.4) | 37 (38.5) | 1.28 | .35 |
| CML | 42 (24.6) | 27 (28.1) | 0.83 | .52 |
| Aplastic anemia | 11 (6.4) | 2 (2.1) | 3.23 | .13 |
| MDS | 14 (8.2) | 9 (9.4) | 0.86 | .74 |
| Lymphoma | 12 (7.0) | 13 (13.5) | 0.48 | .08 |
| Hemoglobinopathy | 6 (3.5) | 2 (2.1) | 1.70 | .52 |
| Immunodeficiency | 10 (5.9) | 6 (6.3) | 0.93 | .89 |
| Donor, no. (%) | ||||
| HLA-matched related | 111 (64.9) | 63 (65.6) | 0.96 | .91 |
| HLA-mismatched related | 14 (8.2) | 11 (11.5) | 0.69 | .38 |
| Unrelated | 46 (26.9) | 22 (22.9) | 1.23 | .47 |
| Graft type, no. (%) | ||||
| cBMT | 50 (29.2) | 27 (28.1) | 1.05 | .85 |
| cPBSCT | 5 (2.9) | 8 (8.4) | 0.33 | .06 |
| TCD-BM | 95 (55.6) | 49 (51.0) | 1.20 | .48 |
| TCD-PB | 20 (11.7) | 12 (12.5) | 0.93 | .85 |
| Cord blood | 1 (0.6) | — | — | — |
| Recipient pretransplantation anti-HBs, no. (%) | ||||
| Negative | 126 (73.7) | 71 (73.9) | 0.98 | .96 |
| Positive† | 37 (21.6) | 21 (21.9) | 0.98 | .96 |
| Unknown anti-HBs, negative core Ab (%) | 8 (4.7) | 4 (4.2) | 1.12 | .84 |
| Donor anti-HBs, no. (%) | ||||
| Negative | 84 (49.1) | 51 (53.1) | 0.85 | .53 |
| Positive‡ | 25 (14.6) | 15 (15.6) | 0.92 | .83 |
| Unknown§ | 62 (36.3) | 29 (31.3) | 1.25 | .41 |
| TBI regimen, no. (%) | 125 (73.5) | 72 (75.0) | .93 | .79 |
| DLI, no. (%) | 37 (21.6) | 28 (29.2) | .67 | .17 |
| Rituximab, no. (%) | 12 (7.0) | 11 (11.4) | .58 | .22 |
| Grade II-IV acute GVHD, no. (%) | 21 (12.3) | 22 (22.9) | .47 | .03 |
| Chronic GVHD, no. (%) | 15 (8.8) | 27 (28.1) | .24 | < .001 |
| Median d to first vaccine (range) | 703 (171-2765) | 778 (181-3444) | .99 | .012 |
| Median age at first vaccine, y (range) | 24 (1.6-60.6) | 36.1 (.8-69.6) | .97 | < .001 |
CML indicates chronic myeloid leukemia; cBMT, competitive bone marrow transplantation; cPBSCT, competitive peripheral-blood stem-cell transplantation; —, not applicable; and Ab, antibody. Additional abbreviations are explained in Table 1.
Data are the simple logistic regression odds ratios of an association between each characteristic and being a responder.
Five of 58 anti-HBs-positive recipients were HepB core antibody positive.
Four of 40 anti-HBs-positive donors were HepB core antibody positive.
One of 91 donors (23 related, 68 unrelated) with unknown anti-HBs status was HepB core antibody positive.